Affiliation:
1. Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120,China
Abstract
Aim and Purpose:
Progressive Stroke (PS) lacks effective treatment measures and leads
to serious disability or death. Retinol binding protein 4 (RBP4) could be closely associated with
acute ischemic stroke (AIS). We aimed to explore plasma RBP4 as a biomarker for detecting the
progression in patients with AIS.
Methods:
Participants of this retrospective study were 234 patients with AIS within the 48 h onset
of disease. The primary endpoint was to ascertain if there was PS through the National Institute of
Health stroke scale (NIHSS); the early prognosis was confirmed through the modified Rankin scale
score (mRS) at discharge or 14 days after the onset of stroke, and the significance of demographic
characteristics and clinical data was determined.
Results:
In this study, 43 of 234 patients demonstrated PS. The level of plasma RBP4 in patients
with progressive stroke was significantly lower (29 mg/L, 22.60-40.38 mg/L) than that without progression
(38.70 mg/L, 27.28-46.40 mg/L, P = 0.003). In patients with lower plasma RBP4, the proportion
of patients with progression (χ2 = 9.63, P = 0.008) and with mRS scores ≥2 (χ2 = 6.73, P
= 0.035) was significantly higher. Multivariate logistic regression analysis showed that a lower
RBP4 level on admission was an independent risk factor for progressive stroke during hospitalization
with an OR value of 2.70 (P = 0.03, 95% CI: 1.12-6.52).
Conclusion:
A low plasma RBP4 level on admission could be an independent risk factor of PS during
hospitalization.
Funder
Guangdong Medical Research Fund Project
Publisher
Bentham Science Publishers Ltd.
Subject
Cellular and Molecular Neuroscience,Developmental Neuroscience,Neurology
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献